Actively Recruiting
Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE
Led by Yu Shi · Updated on 2026-02-17
200
Participants Needed
1
Research Sites
320 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pancreatic ductal adenocarcinoma (PDAC), representing 85-95% of pancreatic cancers, is a highly lethal malignancy with a dismal 5-year survival rate below 8%. Emerging evidence highlights the critical need for non-invasive imaging biomarkers to stratify prognosis and guide therapeutic strategies. Notably, the biomechanical properties of PDAC-associated extracellular matrix (ECM), characterized by extensive interstitial fibrosis, are intrinsically linked to tumorigenesis, progression, and metastatic dissemination. Three-dimensional magnetic resonance elastography (3D-MRE), as an advanced imaging modality, enables precise quantification of tissue shear stiffness in both normal pancreatic parenchyma and neoplastic lesions. Significantly, the biomechanical heterogeneity captured by MRE holds untapped potential to serve as a prognostic biomarker for PDAC. Despite its technical merits, no studies to date have systematically explored MRE-derived imaging signatures in predicting PDAC survival outcomes or therapeutic responses, underscoring a pivotal gap in translational oncology research.
CONDITIONS
Official Title
Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent is provided
- Age 18 years or older
- No history of cancer outside the pancreas
- No preoperative biliary drainage
- Confirmed pancreatic ductal adenocarcinoma by tissue biopsy
- Expected survival of at least three months after surgery or six months of follow-up
You will not qualify if you...
- Inability to re-review tissue specimens
- Poor quality MRE data due to invalid wave data, inconsistent breath holding, intolerable pain, or equipment issues
- Tumor diameter less than 1.0 cm
- Withdrawal or dropout during follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shengjing hospital of China medical university
Shenyang, Liaoning, China, 110004
Actively Recruiting
Research Team
Y
Yu Shi, MD.PhD.
CONTACT
Y
Yang Hong, MD.PhD.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here